Where does CATB stock trade?

Catabasis Pharmaceuticals, Inc. (CATB) is listed on NASDAQ.

What sector and industry is CATB in?

Catabasis Pharmaceuticals, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.

When did Catabasis Pharmaceuticals, Inc. go public?

Catabasis Pharmaceuticals, Inc. (CATB) completed its IPO in 2015.

What are analysts saying about CATB?

Catabasis Pharmaceuticals, Inc. has had 2 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $1600.00 price target on 2021-09-02. Recent price targets range from $1300.00 to $1600.00.

What companies are similar to CATB?

Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare CATB side-by-side with any of them on Quantisnow.

How can I track CATB on Quantisnow?

Quantisnow aggregates Catabasis Pharmaceuticals, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CATB to receive live email and push alerts on every new disclosure.

CATB

NASDAQ

Catabasis Pharmaceuticals, Inc.

SectorHealth CareIndustryMajor PharmaceuticalsIPO2015

$8.57-0.66 (-7.15%)

Follow Website

News25/Ratings2

Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.

Latest news

25 items

CATB FAQ

7 questions

What does Catabasis Pharmaceuticals, Inc. do?
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
Where does CATB stock trade?
Catabasis Pharmaceuticals, Inc. (CATB) is listed on NASDAQ.
What sector and industry is CATB in?
Catabasis Pharmaceuticals, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.
When did Catabasis Pharmaceuticals, Inc. go public?
Catabasis Pharmaceuticals, Inc. (CATB) completed its IPO in 2015.
What are analysts saying about CATB?
Catabasis Pharmaceuticals, Inc. has had 2 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $1600.00 price target on 2021-09-02. Recent price targets range from $1300.00 to $1600.00.
What companies are similar to CATB?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare CATB side-by-side with any of them on Quantisnow.
How can I track CATB on Quantisnow?
Quantisnow aggregates Catabasis Pharmaceuticals, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CATB to receive live email and push alerts on every new disclosure.